XOMA Corp (NASDAQ:XOMA) reported intermediate trial outcomes that showed its candidate XOMA 358 meet expectations in a Phase 2 study. The drug is being developed as a treatment for insulin disorders, which include a condition known as hypoglycemia. The condition can be brought about by post-bariatric surgery (PBS) and congenital hyperinsulinism (CHI).
Study targets met
XOMA Corp (NASDAQ:XOMA)’s XOMA 358 is billed as an allosteric antibody. In the trial, the drug showed favorable outcomes in inhibiting insulin, which in turns shows it can help prevent hypoglycemic episodes.
XOMA 358 is seeking to improve the life of patients who are unable to regulate their insulin properly. The drug is currently being tested in CHI patients.
Besides efficacy, the safety profile of the drug is also being evaluated and it met safety and tolerability targets. No adverse events were reported.
Small number of patients
The reported data only shows outcome in a small number of patients. Though the number of patients is small, the study is expected to help with defining other parameters for improving the efficacy of the drug. That may include continuous glucose monitoring so that the glycemic profile of a patient can be tracked over a period of time such as days and weeks.
Tackling insulin disorders
Insulin abnormalities affect many people of various ages including infants. As such, XOMA Corp (NASDAQ:XOMA)’s XOMA 358 could be a game-changer in addressing an unmet medical need in tackling insulin-related disorders without subjecting patients to adverse risks.
In light of the favorable intermediate Phase 2 data from the study of XOMA 358, XOMA intends to advance the trial of the candidate to Phase 2b. XOMA CEO John Varian expressed confidence that the candidate will continue to produce favorable results throughout the remaining study stages.
XOMA Corp (NASDAQ:XOMA) posted EPS loss of $0.13, missing the consensus estimate of EPS loss of $0.12. Revenue of $0.44 million also fell short of expectation by nearly $0.46 million.